Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.
Project Integrum is a large-scale R&D project designed to discover novel therapeutic antibodies for more than 1000 druggable targets. The project, which was initiated in March 2020, includes the following core milestones:
- Knock-out of 1000 pre-selected drug targets in RenMab TM and/or RenLite ® fully human antibody mice
- Leveraging these target KO RenMice (RenMice HiTS Platform) and high-throughput screening capabilities to establish an off-the-shelf library of fully human antibody hits exhibiting species cross-reactivity, as well as broader sequence and epitope diversity
- Streamlined identification of preclinical candidates (PCC) using Biocytogen’s innovative mouse models and in vivo/in vitro pharmacology platforms
- Development of antibody candidates into various drug modalities through joint or internal research, including monoclonal antibodies, bispecific antibodies, and ADCs.
The company has officially completed the first two milestones on schedule; nearly 1000 target KO RenMice® strains have been generated, more than 900 target antibody discovery projects have been completed, and a library containing 400-500K fully human antibody sequences has been established. 30+ PCC-stage molecules have also been successfully identified.
The rapid progress of the project has directly led to the exponential growth of Biocytogen’s antibody licensing and co-development business, with 50 antibody asset-based co-development/out-licensing/transfer agreements established, including partnerships with 6 multinational pharmaceutical companies. In addition, 5 collaborative products are expected to submit IND applications and start clinical trials in 2024. As the number of co-development products entering clinical trials increases, Biocytogen's ongoing business growth will be fueled not only by upfront payments but also by milestone payments.
As Project Integrum shifts focus to the latter milestones, the company will work with collaborators to expedite the development of selected antibodies against key targets to enter into the clinic.
Dr. Yuelei Shen, President and CEO of Biocytogen, said: “Project Integrum aims to overcome several difficulties in the field, such as crowded target selection and high cost, time-consuming antibody discovery. Species cross-reactive fully human antibodies derived from our platform can significantly reduce preclinical research time and cost, while improving the rate of translational success. We adopt an open, flexible and diverse business model to share our antibody repertoire and resources with global partners to reduce their development costs and increase the success rate by minimizing redundant investments and improving resource utilization efficiency. We welcome more collaborators to join us in this endeavor, working together to develop better antibody drugs that will benefit patients.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice® HiTS Platform). As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817088666/en/
Contact information
Biocytogen
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease8.1.2026 14:00:00 EET | Press release
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine. Results support further development of V-212 independently and in combination with an approved PCV. “With the significant need for an effective serotype-independent vaccine, we are pleased to report positive results, which highlight the excellent safety profile and immunogenicity of V-212 and, more broadly, validate our Synthetic Virus-Like Particle (SVLP) platform approach for the development of broad-spectrum, self-adjuvanted vaccines with high
Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base8.1.2026 13:36:00 EET | Press release
Abbelight, a global leader and a pioneer in super-resolution microscopy end-to-end solutions, today announced a successful Series B financing round led by AVANT BIO, a growth equity firm focused on enabling technologies shaping tomorrow’s therapeutics. “With a decade of experience in the Life Science Research market, Abbelight has been transforming the way scientists see, quantify, and interpret all kinds of complex intracellular mechanisms. It’s now time to tailor our cutting-edge imaging toolbox to also address new key verticals, such as single cell phenotyping and mechanisms of action validation for drug discovery”, says Nicolas Bourg CTO and co-founder. “Big things happen at the nanoscale - and Abbelight enables researchers to visualize precise sub-cellular structures like never before”, said Daniella Kranjac, Founding General Partner at AVANT BIO. “Their breakthroughs in super-resolution microscopy and sample-to-insight workflows embody the kind of enabling technologies that accel
FGS Global launches 2026 Radar Report: "A Rewired World"8.1.2026 12:00:00 EET | Press release
The post-war global order is fragmenting into spheres of influence as strongman leadership and transactional relationships replace multilateral cooperation, according to FGS Global's Radar 2026 report released today. FGS Global’s Radar is based on 175 in-depth interviews with senior global leaders and policy experts from the worlds of business, politics, academia and media and wide ranging, nationally representative polling of approximately 20,000 people across the US, Canada, the member countries of the European Union and Japan. We are in a Rewired World reshaped by the collapse of multilateral consensus and the rise of strongman leadership over weakened institutions. US-China competition is intensifying across trade, technology and space while traditional alliances fracture. At the same time, AI-driven disruption is accelerating change, populist disruptors are challenging established systems and influence is atomizing as mainstream media and political parties lose ground. The implica
GEOLOG Acquires Quad Ltd and QO Inc. to Enhance Global Wellsite Geology and Pore Pressure Services8.1.2026 12:00:00 EET | Press release
GEOLOG International B.V. (“GEOLOG” or the “Company”), a leading independent provider of wellsite geosciences, drilling solutions and surface logging services to the energy industry, today announced the successful acquisition of Quad Ltd and QO Inc. (together, “Quad”). Quad is a long-standing provider of wellsite and operations geologists, along with advanced pore pressure and fracture gradient analysis services. This strategic bolt-on acquisition significantly enhances GEOLOG’s portfolio of advanced subsurface and drilling support services and solidifies its operational presence globally. GEOLOG and Quad have a history of successful collaboration on numerous international projects, serving a broad spectrum of energy clients. Integrating Quad’s highly experienced personnel and specialized technical capabilities will strengthen GEOLOG’s capacity to support clients in complex drilling environments, spanning from exploration through development and production phases. “Quad has been a trus
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 11:03:00 EET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom